摘要
目的观察评估Bevacizumab在临床治疗增生期糖尿病视网膜病变(PDR)、糖尿病视网膜病变(DR)视网膜缺血后虹膜睫状体新生血管形成并发新生血管性青光眼(NVG)等眼内新生血管性疾病的疗效。方法回顾性分析78例(78只眼)病例资料,其中PDR患者32例(32只眼);DR继发NVG者20例(20只眼);视网膜中央静脉阻塞(CRVO)缺血型致黄斑水肿26例(26只眼)。均接受玻璃体腔内注射安全常规剂量Bevacizumab后,观察最佳矫正视力(BCVA)、相干光断层扫描(OCT)显示黄斑中心视网膜厚度(CMT)、眼压(IOP)的结果与治疗前对比分析。随访2～12个月。结果 Bevacizumab治疗后与治疗前比较,视力明显提高(P<0.001),OCT示CMT明显变薄(P<0.001),黄斑水肿减轻,IOP较治疗前明显降低(P<0.001)。未见与药物有关的眼部和全身不良反应。结论玻璃体腔内注射Bevacizumab,可以显著降低复杂眼内新生血管性疾病的手术难度,明显减轻黄斑水肿,提高视力,但长期治疗效果需要进一步观察。
Objective To investigate the clinical efficacy of intravitreal injection of Bevacizumab as the treatment for neovascularization disease.Methods The research is retrospective,noncomparative,and co-nsecutive.Bevacizumab was injected intravitreally in 78 eyes of 78 pati-ents with neovascularization.Among the patients,proliferative diabetic r-etinopathy（PDR） were 32 eyes and neovascular glaucoma（NVG） secondary to diabetic retinopathy（DR） were 20 eyes.The macular edema caused by ischemic type of central rentinal vein occlusion（CRVO） were 26 eyes.The best corrected visual acuity（BCVA）,intraocular pressure（IOP）,fundus fluorescence angiography（FFA） and the central macular thickness（CMT） under the optic coherence tomography（OCT） were recorded and analyzed prior to operation and after operation.Follow-up time was 2 months to 1 year.Results CMT in treatment group became obviously thinner（P〈0.001）,The mean IOP after injection were signif-ycantly lower than preinjection（P〈0.001）.The visual acuity of the treatment group increased more than that of preinjection（P〈0.001）.The untoward reaction of Bevacizumab not been discovered.Conclusion Intravitreal injection of Bevacizumab is a safe and effective methods for neovascularization disease and could reduce the difficulty of the intraocular operation.But the therapeutic effect for long time need a further observation.
出处
《临床眼科杂志》
2010年第5期438-440,共3页
Journal of Clinical Ophthalmology
